Skip to main content

Table 1 Baseline characteristics of study participants

From: Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

Characteristics

N

%

Sex, n (%)

 Male

20

52.6

 Female

18

47.4

Age, years

 Median (Q1-Q3)

49 (40–53.25)

 

 Min–max

28–60

 

Previous COVID-19 infection

 Before the primary vaccine

4

12.5

 After the primary vaccine

4

12.5

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us